Literature DB >> 913984

Current status of the precancer lesion in ulcerative colitis.

W O Dobbins.   

Abstract

Entities:  

Mesh:

Year:  1977        PMID: 913984

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  7 in total

Review 1.  Cancer in inflammatory bowel disease.

Authors:  A J Greenstein; A Sugita; Y Yamazaki
Journal:  Jpn J Surg       Date:  1989-11

2.  Immunohistochemical evaluation of carcinoembryonic antigen, secretory component, and epithelial IgA in ulcerative colitis with dysplasia.

Authors:  T O Rognum; K Elgjo; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1982-02       Impact factor: 23.059

3.  Combining aneuploidy and dysplasia for colitis' cancer risk assessment outperforms current surveillance efficiency: a meta-analysis.

Authors:  Rüdiger Meyer; Sandra Freitag-Wolf; Silke Blindow; Jürgen Büning; Jens K Habermann
Journal:  Int J Colorectal Dis       Date:  2016-10-20       Impact factor: 2.571

4.  Ulcerative colitis with overexpression of p53 preceding overt histological abnormalities of the epithelium.

Authors:  K Matsuda; H Watanabe; Y Ajioka; M Kobayashi; H Saito; M Sasaki; K Yasuda; A Kuwabara; K Nishikura; T Muto
Journal:  J Gastroenterol       Date:  1996-12       Impact factor: 7.527

5.  The risk of cancer following colectomy and ileorectal anastomosis for extensive mucosal ulcerative colitis.

Authors:  S F Grundfest; V Fazio; R A Weiss; D Jagelman; I Lavery; F L Weakley; R B Turnbull
Journal:  Ann Surg       Date:  1981-01       Impact factor: 12.969

6.  Crohn's disease and adenocarcinoma of the bowel.

Authors:  J Traube; S Simpson; R H Riddell; B Levin; J B Kirsner
Journal:  Dig Dis Sci       Date:  1980-12       Impact factor: 3.199

7.  Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program.

Authors:  B A Lashner; M D Silverstein; S B Hanauer
Journal:  Dig Dis Sci       Date:  1989-10       Impact factor: 3.199

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.